An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's
An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's flagship Plug n View 3D and Voxar Colonscreen products. The package automates the identification of calcified plaques in the coronary arteries and calculates the calcium score, providing the basis for assessing potential risk and managing associated coronary heart disease before symptoms arise. Calscreen 2.1 works with electron-beam tomography scanners and multislice or helical CTs. The package, which runs on a standard PC, automatically highlights calcified regions in red as part of multiplanar reformatted (MPR) and 3D views of the heart.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.